Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporos...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jolan Dupont, Wesley Appermans, Marian Dejaeger, Isabelle Wauters, Michaël R. Laurent, Evelien Gielen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2022-06-01
Edice:	Bone Reports
Témata:	Bone turnover markers Denosumab Osteoporosis Vertebral fractures Rebound phenomenon
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2352187222004168
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!